| Bioactivity | SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively[1]. | |||||||||
| Invitro | SRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity[1]. | |||||||||
| Name | SRI-29329 | |||||||||
| CAS | 2086809-58-5 | |||||||||
| Formula | C20H26ClN7 | |||||||||
| Molar Mass | 399.92 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Yihui Shi, et al. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. |
SRI-29329
CAS: 2086809-58-5 F: C20H26ClN7 W: 399.92
SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.